Epbriv 0.44 Injection 2 ml

Epbriv 0.44 Injection 2 ml belongs to a group of medicines known as 'anti-cancer' used to treat various cancers, including breast and liposarcoma. Cancer is a condition where cells in a specific body part grow and reproduce uncontrollably. Breast cancer is cancer that forms in the cells of the breasts. A liposarcoma is a rare cancer that develops in your fatty tissue.

Epbriv 0.44 Injection 2 ml contains Eribulin, which works by stopping the cancer cells from separating into two new cells. So, it blocks the growth of the cancer.

Epbriv 0.44 Injection 2 ml should be administered to patients only in a hospital setting under the supervision of a physician qualified by training and experience to administer cancer chemotherapeutic agents. The most common adverse reactions that occur while on therapy are neutropenia (lower-than-normal levels of neutrophils), anaemia (lack of blood), asthenia (weakness), fatigue(tiredness), alopecia (hair loss), peripheral neuropathy (Weakness, numbness, and pain from nerve damage), nausea, and constipation. Most of these side effects of Epbriv 0.44 Injection 2 ml do not require medical attention and gradually resolve over time. However, if the side effects persist, contact your doctor.

To treat your condition effectually, continue taking Epbriv 0.44 Injection 2 ml for as long as your doctor has prescribed. Do not stop using the Epbriv 0.44 Injection 2 ml midway. It is expected to cause fetal harm when administered to a pregnant woman, so it should not be used in pregnant women. Both women and men using this Epbriv 0.44 Injection 2 ml should use birth control to avoid pregnancy. Discontinue nursing while on therapy, considering the importance of the drug to the mother. Caution should be exercised while using Epbriv 0.44 Injection 2 ml in patients with hepatic, renal, heart dysfunction and or Neutropenia (Lower-than-normal levels of neutrophils), so inform your doctor about all your medical conditions and medications you are currently taking.

Epbriv 0.44 Injection 2 ml contains Eribulin, which belongs to a group of medicines known as 'anti-cancer' used to treat various types of cancers, including breast and liposarcoma. It works by stopping the cancer cells from separating into two new cells. So, it blocks the growth of the cancer.

Before taking the Epbriv 0.44 Injection 2 ml, let your doctor know about all your allergic or hypersensitivity reactions to medicines or food. Before taking Epbriv 0.44 Injection 2 ml, inform your doctor about your medical history and other medications you are currently taking in order to rule out any potential negative effects. Epbriv 0.44 Injection 2 ml may cause permanent fertility problems in men if they take it. Please discuss this with their doctor before starting treatment. Women of childbearing age should use effective contraception during and up to 3 months after treatment with Epbriv 0.44 Injection 2 ml. Avoid the consumption of alcoholic beverages and grapefruit juices.